



Springer Healthcare

All about Adis.... an overview of us and our journals

Jan Seal-Roberts -Publishing Director

Presented at MedComms Networking Event – 5 Dec 2018

www.MedCommsNetworking.com

Who are ADIS, and what do we do?

- We are officially ‘Springer Healthcare’ - part of **Springer Nature**
- We currently publish **33 journals**, all focusing on drugs and disease therapy
- Our **Adis ‘Premier’ journals** are mostly subscription-based, with high Impact Factors, and Medline indexing
- Our **Adis ‘Rapid+’ journals** are mostly open access, offering rapid publication for all articles, and a personal service for authors and industry
- Both portfolios offer large, global readerships and fast timelines
- And we are great to work with!





Adis Premier portfolio



High Impact

Open Choice/Open Access

Timely Processing

VIP Option



Adis 'Premier' journals

- **High impact**
 - Average Impact Factor 3.0 (1.362 – 4.690)
 - Many are top-ranked journals within their field, and represent some of Springer Nature's most downloaded titles
 - Distributed to institutions as part of Springer's Hospital/ Healthcare global consortia package
- **Primarily subscription based, but with open access option ('Open choice')**
 - Optional OA (currently \$3000 / €2200)
 - Although some of the newer titles are fully OA (with fixed APCs)
- **Timely processing:** Peer review: 4 - 6 weeks
Then online within 2 - 3 weeks of acceptance
- **VIP service option:** 10-day peer review (NB: with advanced warning)
Online within 10 - 15 days of acceptance (cost: € 12,000)

Almost everyone knows *Drugs* (Adis Premier's flagship journal)



**One of the most
downloaded journals
within Springer Nature!**

Content: Late phase key research, reviews , HEOR data (does not publish case reports)

Editor in Chief: Dene Peters

Impact Factor: 4.690

CiteScore: 4.72

Indexed: PubMed/Medline + all major indexing databases

Readership: 615,000

Open Access option: currently \$3000 / € 2200


Aims and scope:

- Promotes optimal drug therapy among all HCPs by publishing pivotal research and reviews on the latest & most important aspects of clinical drug use
- Pivotal research (including selected P2 trials, and P3 or 4 research, reviews of drugs or disease areas)
- Also includes Adis Drug Reviews (DEs, AdisInsight Reports)

Some of our other key Adis Premier titles...



And some of our therapy-focused titles....




Adis Rapid+ portfolio



Open Access




Rapid Publication



Enhanced Features



Return on Investment



Adis 'Rapid+' journals

- **Fully open access** (NB: *Advances in Therapy* is Open Choice)
- **Rapid publication:** 2 weeks for peer review. Acceptance to online in 3 - 4 weeks
- **Inclusive:** Positive, negative and confirmatory data are all welcomed, including post-hoc studies, trial designs, country-specific data etc.
- **And we have a dedicated in-house UK journal team that is always happy to help!**
 - In-house styling /formatting can be provided by Adis staff (at no extra cost)
 - We can submit papers on behalf of authors – saving everyone time and effort
 - We are happy to copy in pharma/med comms contacts alongside standard author correspondence, if required
 - We can gladly provide advice and guidance to authors re the best ways to use social media to boost dissemination

Advances in Therapy



**One of Springer
Nature's most
highly-read
journals!**

Impact Factor: 3.085

CiteScore 3.01

Indexed: PubMed/Medline + all major indexing databases

Readership: 710,000

Fees: €580/\$660 per typeset page

OA option: currently \$3000/ €2200


Broad aims and scope: International, peer-reviewed journal dedicated to the rapid publication of all types of preclinical and clinical research, case reports, plus authoritative reviews in all fields relating to clinical medicine.

Content: Clinical (all phases), observational, real-world, and health outcomes research. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged. Narrative, systematic, and literature reviews are also welcomed.

Some of our other Rapid+ journals:



All Adis journals provide article usage metrics via SpringerLink



The screenshot shows the SpringerLink interface for an article. The article title is "Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study". The authors listed are Gregory J. Feldman, Ana R. Sousa, David A. Lipson, Lee Tombs, Neil Barnes, John H. Riley, Sadhana Patel, Ian Naya, Chris Compton, and Bernardino Alcazar Navarrete. The usage metrics are circled in red: 40 Shares, 32k Downloads, and 7 Citations.

Metric	Value
Shares	40
Downloads	32k
Citations	7

Further metrics (e.g. Altmetrics, access via PubMed/Google) are also available – just ask!

So what else can we offer...?

Well – there's so much more!

The Adis **pre-submission service**

- Personalized service, provided in confidence and without obligation
- Can be given on basis of full manuscript, abstract (with title) or outline
- Enquiries to caroline.halford@springer.com
- The team will contact all appropriate Adis Editors, who then advise re likely suitability of the envisaged submission for their journal
- **Responses are usually provided within 48 hours**
- We then provide a list of all appropriate Adis journals likely to consider the paper (subject to peer review) plus relevant details (including IF, likely timeline, any costs, etc.)
- The contact can then decide (with no obligation)



**“Just call
Caroline!!”**

All our Adis journals welcome **Plain Language Summaries**

PLSs are brief summaries of published research aimed at non-experts to facilitate readability and ease of understanding of a research article,

- explaining why the research was done, and its aim
- and also explaining the results and likely impact

Overall aim: to achieve greater impact of reported outcomes via increased understanding and wider audience reach

PLSs are usually submitted with a paper – but can follow a submission if necessary (but will still be peer reviewed – of course!)

Adis digital features

- **Adis Rapid+ journals** can accept DFs (either submitted with the manuscript, or added post-publication)
- **Adis Premier journals** prefer DFs to be submitted with the manuscript (but may accept these post-acceptance if necessary)
- **All digital features are peer reviewed**
- Authors retain the copyright of the DFs in each case
- DFs are hosted open access on FigShare for maximum 'findability'
- Multiple features can be published per article
- And we can coordinate simultaneous manuscript + feature publication, if necessary

- However, all digital content must (of course!):
 1. reflect the data within the manuscript
 2. be fair and balanced
 3. be scientifically accurate

Video abstracts

Audioslides

Slide sets

Educational
videos

Animations

Surgical/practical
videos

Video articles

The **Adis Drug Evaluation Programme**

A unique range of definitive drug reviews written by Adis on approved drugs:

- **AdisInsight Reports**

Brief summaries of a new drug, published within 6 weeks of first approval

- **Adis Drug Evaluations**

Comprehensive, evaluative reviews, placing a drug in clinical context

- **Adis Biosimilar Briefs**

Evaluative reviews for biosimilars

- **Adis Q&A articles**

Practical guides on the use of a drug, set in context of available data

All of these articles are totally independent, developed by our expert Adis writers at our own cost on the basis of available data. These are rigorously peer reviewed – but we also welcome pharma input in each case to ensure accuracy and completeness

The Adis DE programme

AdisInsight Reports

6 weeks

5 – 6 months

Adis Q&A articles

1 - 2 months

Adis Biosimilar Brief (ABB)

3 months

But what do our pharma/agency contacts say?

I would like to take this opportunity to express my admiration for AIT. You guys must be world ranked #1 for speed and efficiency.

Thanks a million for the fantastic service!

We thank you very much. You are a pleasure to work with.

It was a pleasure working with you again! And I am looking forward to our next project!

I am in research since 25 years and have never had such a nice considerate email on follow up of the review process of a manuscript! This is very kind to keep us informed

Thank you for everything – it's a true pleasure working with such professionals.



Thank you!

Your support and help are invaluable. I look forward to a continued association with you.

The service has been nothing but superb!

So in summary - **What does Adis do...?**

- We are real people (honestly!) who **talk to pharma and med comms agencies daily** about their data and publishing needs
- We are very well known for **developing some of the very best reviews in the business** (our Adis Drug Evaluations) which have a world-class reputation for their quality and objectivity
- But we also work hard to ensure that our Adis journals publish **high-quality original research** to inform our global readership – and offer a range of journals to provide more **‘inclusive’ options for all scientifically sound research**
- We provide a **very popular pre-submission service** to help authors and publication planners ‘get it right first time’ - and can even help with the formatting and submission process for our Adis Rapid+ titles
- And our **timelines really are impressive** – just try us and see for yourselves!

But most of all....

- We aim to be helpful and transparent in all we do – and are keen to ensure that **everything we publish is given the best chance possible to maximise its impact on our global readership**, primarily via stringent peer-review and clear page layout – but we also offer the opportunity to include digital features and plain language summaries, and can also advise re how best to leverage social media potential

So do let us know how Adis can help you!

Thank you!



[Jan Seal-Roberts](#)

[Publishing Director, Adis](#)

jan.seal-roberts@springer.com



[Caroline Halford](#)

[Digital Publishing Manager, Adis](#)

caroline.halford@springer.com